Outlook

ENGLISH DEUTSCH

News flow

RENCAREX®
  • Decision: product or $15m / $20m cash from Prometheus
  • Full study results of final DFS analysis expected in Q4 2012
MESUPRON®
  •  Breast cancer Phase II trial PFS data expected 2012
WX-554
  • Start Phase I with oral WX-554 in cancer patients
WX-037
  • Preclinical research and development will continue
REDECTANE®
  • Decision on further development and approval process
  • FDA feedback on Advisory Committee
In-vitro diagnostics  
  • Increase marketing activities and revenue
 ADC + CSR
  • Third-party ADC collaborations
  • Increase sales revenue

Financial outlook

  Guidance 2012
EUR m		  ACT 2011
EUR m
Sales revenue and other income 14.0 – 16.0 11.7
Operating expenses 25.0 – 29.0 25.1
Operating result (EBIT) (10.0) – (14.0) (13.4)
Total funding requirement 20.0 – 24.0 24.0
Funds required per month 1.7 – 2.0 2.0
Print This Page Print This Page | Email This Page Email This Page    
Seite gelesen: 158 | Heute: 4